Ergebnis der Suchanfrage nach Celle
Inhalte
- Kategorie:
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
Aston Martin Lagonda of Europe GmbH
10New Aston Martin Vantage GT4 completes top-flight line-up of production-based GT racers
mehr- 4
GEA at the Anuga FoodTec trade show: Sustainability innovations bolster food industry resilience
Ein Dokumentmehr Therapeutic Vaccine for Chronic Hepatitis B Enters Clinical Trial
mehrWhat Our Genetic Information Tells Us About Type 2 Diabetes Risk and Complications
mehrHearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy ...
mehr- 3
GEA invests EUR 18 million in technology center for alternative proteins in the USA
Ein Dokumentmehr Aston Martin Lagonda of Europe GmbH
10STATE-OF-THE-ART ASTON MARTIN VANTAGE GT3 SPEARHEADS NEW ERA IN TOP-FLIGHT GT RACING
mehrPolaroid Therapeutics completes pre-clinical milestones in the development of superior antimicrobial technology for acute and chronic wounds
Bern, Switzerland (ots/PRNewswire) - - Its proprietary innovative polymer technology reduces bacterial bioburden without triggering antimicrobial resistance, one of the top global public health threats - The Advanced Wound Dressing (AWD) market is valued at 4.5 billion USD and is witnessing increasing demand and ...
mehr- 2
PM: DHL Group mit Wasserstoff-LKWs im Rheinland unterwegs / PR: DHL Group deploying hydrogen trucks in Germany
2 Dokumentemehr Strengthening the Direct Sales and Service System for Business Expansion in Italy
Ein DokumentmehrBiomay Announces its Successful Support of Approval of First CRISPR/Cas9-based Therapy
mehrHigh-tech fab in Dresden receives state-of-the-art electron-beam lithography system
Jena (ots) - Investment in new production tool for the semiconductor equipment industry. Jenoptik is investing a low double-digit million-euro amount in a state-of-the-art system for the high-tech fab currently under construction in Dresden. The new electron-beam lithography system (E-Beam) will be used to manufacture high-precision micro-optical components for ...
mehrPress release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...
Ein DokumentmehrAcousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
Tübingen (ots) - - German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh ...
mehrMedison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
Zug, Switzerland (ots/PRNewswire) - - Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory ...
mehrBioVaxys Executes Letter of Intent for Major Immunotherapeutics Technology Acquisition
Vancouver, Bc (ots/PRNewswire) - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that it has executed a non-binding Letter of Intent ("LOI") to acquire the core platform technology and entire immunotherapeutics intellectual property portfolio of discovery, preclinical development, and Phase II clinical study ...
mehrBioVaxys and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare
Vancouver, Bc (ots/PRNewswire) - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that as part of BioVaxys' efforts to refocus on immunotherapeutics, Biovaxys and Procare Health ("Procare") have jointly and amicably agreed to terminate the US Distribution Agreement for Papilocare and Immunocaps. The partnership ...
mehrCells of the Future: A Key To Reprogramming Cell Identities
mehrNew Source of Stem Cells in Injury-Affected Brains of Patients
mehrEnergy at its best: German battery pioneer CustomCells unveils new brand identity
mehrFraunhofer-Institut für Produktionstechnologie IPT
Pooling expertise: Fraunhofer IPT and Harro Höfliger cooperate in the manufacturing of ATMP production systems
mehrTen benefits of a daily intake of citrus fruits during winter season
mehrBiomay Announces Expansion of GMP-Facilities to Offer mRNA Manufacturing and Aseptic Filling Services
mehrVisIC Technologies Revolutionizes Automotive Power Electronics with V22TG D3GAN in Advanced Top Side Cooled Isolated Package
Ness Ziona, Israel (ots/PRNewswire) - VisIC Technologies Ltd, a global leader in advanced GaN power electronics solutions, is excited to introduce the highly anticipated V22TG D3GAN power package. This revolutionary power package, housed in an advanced gull wing leaded top side cooled isolated package, sets new ...
mehrTrade Fair Innovation: Universal 3D Printing Software
Ein DokumentmehrSoterios Pharma completes Phase II enrolment for STS-01 in mild / moderate (patchy) alopecia areata
London (ots/PRNewswire) - Soterios Pharma, a privately held clinical-stage pharmaceutical company, announced today that it has completed target enrolment for its Phase II trial with STS-01 for mild / moderate (patchy) alopecia areata. Final results of the study are anticipated to be available in Q2 2024. David Fleet, CEO of Soterios Pharma, said, "This represents an ...
mehrTechnische Universität München
Start-up dedicated to developing new antibiotics
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Smartbax nominated for Falling Walls award Start-up dedicated to developing new antibiotics • New approach against resistant pathogens • Agent damages protein transport and energy balance of bacteria • Two TUM spin-offs nominated for Science Breakthrough of the Year at Falling Walls Summit It all began with basic research: While conducting laboratory experiments, a team ...
mehr- 5
Reflecting on a successful Pharma Forum 2023
Ein Dokumentmehr - 2
Quantum leap in battery technology / German start-up develops the world’s first solid-state battery ready for series production – Outstanding properties: no cobalt, 10 times longer service life and non-flammable electrolyte
mehr